Table 3 Latent class analysis adjusted to class probability

Type of treatment

Drug (ref)

hESCs

-0.52**

0.17

-0.86–-0.18

1.28***

0.19

0.92–1.65

1.13***

0.11

0.91–1.36

iPS cells

-0.64***

0.18

-0.98–-0.29

0.91***

0.18

0.57–1.26

1.09***

0.11

0.88–1.31

Electric stimulation

-1.41***

0.26

-1.93–-0.89

0.61**

0.22

0.18–1.04

0.95***

0.17

0.60–1.31

Aim of treatment

Symptom relief (ref)

Slow down disease progression

0.31

0.20

-0.07–0.70

1.16***

0.25

0.67–1.65

1.08***

0.14

0.62–1.29

Repair damage caused by disease

0.35

0.24

-0.13-0.82

1.66***

0.27

1.13–2.19

1.08***

0.15

0.81–1.34

Number of patients who have received the treatment

50 (ref)

500

0.39*

0.17

0.07–0.72

0.22**

0.12

-0.01–0.45

0.16

0.08

0.79–1.38

5000

0.77***

0.17

0.44–1.09

0.37***

0.14

0.09–0.65

-0.16

0.09

-0.00–0.33

Effect on symptoms

2 in 10 (ref)

5 in 10

0.81***

0.22

0.37–1.24

1.87***

0.24

1.40–2.34

0.14

0.13

-0.33–0.02

8 in 10

1.55***

0.27

1.01–2.09

3.14***

0.32

2.52–3.76

0.15

0.19

-0.12–0.40

Risk of severe side effects

1 in 1000

0.90***

0.20

0.50–1.29

2.13***

0.27

1.60–2.66

-0.04

0.14

-0.21–0.52

10 in 1000

0.53**

0.18

0.18–0.89

0.92***

0.19

0.59–1.28

-0.15

0.10

-0.31–0.22

20 in 1000 (ref)

Class probability model

Treatment experience (summary of pharmacological treatments tested)

0.26***

0.04

-0.18–0.34

0.13***

0.04

0.05–0.20

Experience with side effects (summary of all experienced side effects)

0.09***

0.02

0.04–0.14

0.13***

0.02

0.09–0.18

Experience with advanced treatment

1.21***

0.26

0.71–1.72

1.62***

0.24

1.16–2.09

Religion (yes or no)

-0.92***

0.17

-1.26–-0.59

-0.68***

0.14

-0.94–-0.40

Average class probability

0.38

0.23

0.37

*,**,*** indicate significance at 10%, 5%, and 1%, respectively.